NYSE:SEM
NYSE:SEMHealthcare

Is Select Medical (SEM) Undervalued After Recent Share Price Rebound?

Select Medical Holdings (SEM) has quietly outperformed the broader healthcare space over the past 3 months, even as the stock remains down sharply year to date. That mix of recent momentum and earlier weakness is exactly what catches valuation driven investors’ attention. See our latest analysis for Select Medical Holdings. At a share price of $15.01, the stock has clawed back some ground with a 30 day share price return of nearly 10 percent and an 18 percent gain over 90 days. However, that...
NYSE:ENS
NYSE:ENSElectrical

How Investors Are Reacting To EnerSys (ENS) BTIG Upgrade Highlighting Data Center and Storage Demand

Earlier this month, BTIG upgraded EnerSys from Neutral to Buy, citing expected demand growth for its Energy Systems unit that supplies data centers and large-scale energy storage projects. The upgrade shines a light on Energy Systems as a potential primary growth engine for EnerSys, reflecting how data center expansion and the broader energy transition are reshaping the company’s business mix. Next, we’ll examine how expectations for faster growth in the Energy Systems segment could...
NYSE:SYK
NYSE:SYKMedical Equipment

Stryker (SYK): Reassessing Valuation After Dividend Hike and Parnassus Endorsement

Stryker (SYK) just paired a 5% dividend hike with a fresh vote of confidence from Parnassus Investments, and together those signals are encouraging investors to revisit the stock after a soft stretch. See our latest analysis for Stryker. That message lands at a time when momentum has cooled a bit, with the latest share price at $355.2 and a slightly negative year to date share price return, but a markedly stronger three and five year total shareholder return suggesting the longer term...
NYSE:CAG
NYSE:CAGFood

Conagra Brands (CAG) Swings to $663.6m Q2 Loss, Undercutting Earnings-Recovery Narrative

Conagra Brands (CAG) just posted a tough Q2 2026, with revenue of $3.0 billion and Basic EPS of -$1.39 as net income swung to a loss of $663.6 million. On a trailing 12 month basis, EPS stood at -$0.20 on $11.2 billion in revenue and net income of -$98 million. Over the last six reported quarters, the company has seen quarterly revenue move between $2.6 billion and $3.2 billion, alongside EPS ranging from $0.30 to $0.97 before this latest negative print. This sets up a story where margins...
NasdaqGS:CTAS
NasdaqGS:CTASCommercial Services

Cintas (CTAS) Valuation After Q2 Earnings Beat and Upgraded 2026 Outlook

Cintas (CTAS) just turned in another earnings win, topping second quarter expectations on both revenue and profit while lifting its 2026 sales and EPS outlook, a combination that tends to grab investor attention. See our latest analysis for Cintas. The latest beat and higher 2026 guidance arrive in a mixed trading backdrop, with the share price at $187.57 after a softer 90 day share price return of 7.41 percent and a far stronger five year total shareholder return of 132.11 percent. This...
NYSE:GME
NYSE:GMESpecialty Retail

Is GameStop’s Recent Slide a Chance or a Warning After Conflicting Valuation Signals?

How GameStop Has Really Performed for Shareholders With all the noise around GameStop, it is easy to forget that underneath the memes and message boards sits a real business with a very real share price history. Looking at that record in detail helps separate durable value from short term hype. Over the last five years, early believers have done very well. GameStop shares are still up more than 350% across that period, even after the dust from the 2021 short squeeze and subsequent volatility...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Does Coupang’s Recent Pullback Offer Value as DCF and PE Send Mixed Signals?

Wondering if Coupang's current share price actually reflects its long term potential, or if the market is missing something? This breakdown will walk you through what the numbers are really saying. Despite being up 53.3% over the last 3 years, the stock has been choppy lately, slipping 9.5% over the past week and 13.0% over the last month, while still clinging to a modest 4.1% gain year to date. Recent headlines have focused on Coupang's ongoing push to deepen its logistics moat in Korea and...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike (CRWD) Valuation Check After Falcon AIDR Launch and New Amazon, SailPoint Partnerships

CrowdStrike Holdings (CRWD) has been in focus after rolling out its Falcon AI Detection and Response product, while also landing deeper ties with Amazon Business Prime and SailPoint, moves that quietly expand its AI era security footprint. See our latest analysis for CrowdStrike Holdings. All of this comes after a strong run, with CrowdStrike’s latest share price at $481.28 and a robust year to date share price return of 38.56 percent. Its three year total shareholder return of 371.89 percent...
NYSE:S
NYSE:SSoftware

SentinelOne (S): Reassessing Valuation After Strong Results, Softer Guidance and CFO Exit

SentinelOne (S) just delivered a quarter with double digit revenue growth and a clean move into positive margins, yet the stock is under pressure after softer guidance and a surprise CFO departure. See our latest analysis for SentinelOne. Those mixed signals help explain why, even with operational wins and high profile threat discoveries, SentinelOne’s share price return is still negative over the last year while the three year total shareholder return remains in positive territory. This...
NYSE:WAL
NYSE:WALBanks

Is Western Alliance Still Attractively Priced After Its Post Banking Jitters Recovery?

If you have been wondering whether Western Alliance Bancorporation is still a bargain after its recovery, you are not alone. This stock has quietly become one of the more interesting value stories in regional banking. The share price closed at $86.36 recently and, despite a slightly softer 7 day return of -1.4%, it is still up 9.1% over the last month, 4.2% year to date, and about 4.0% over the past year, with a strong 59.7% gain over three years that hints at substantial long term...
NYSE:NVT
NYSE:NVTElectrical

Assessing nVent Electric (NVT) Valuation After Its Confident Quarterly Dividend Increase

nVent Electric (NYSE:NVT) just gave income investors a small raise, boosting its quarterly dividend 5% to 0.21 dollars per share for the first quarter of 2026, a clear nod to management's confidence. See our latest analysis for nVent Electric. The market seems to agree with that confidence, with the share price at 101.54 dollars after a strong year to date share price return of 48.32 percent and a standout five year total shareholder return of 376.33 percent. This suggests momentum remains...
NYSE:ACM
NYSE:ACMConstruction

AECOM (ACM): Valuation Check After Winning Brisbane 2032 Olympic Infrastructure Program Management Role

AECOM (ACM) just landed a marquee role for the Brisbane 2032 Olympics, helping lead nearly $5 billion in infrastructure projects through its Unite32 joint venture, creating a long-duration project pipeline that could be significant for the stock. See our latest analysis for AECOM. Despite landing a string of long dated contracts with Brisbane 2032, the FAA and the U.S. government, AECOM’s share price return has slid in recent months. Its five year total shareholder return remains strongly...
NYSE:RDW
NYSE:RDWAerospace & Defense

Redwire (RDW): Evaluating Valuation After New Eight-Figure European Docking Systems Agreement

Redwire (RDW) just landed an eight-figure agreement with Germany-based The Exploration Company to supply two docking systems for its Nyx spacecraft, and the stock quickly reacted to the news. See our latest analysis for Redwire. The contract news comes after a volatile stretch for Redwire, with a 1 month share price return of about 51 percent but a year to date share price return still down sharply, while the 3 year total shareholder return above 300 percent shows that long term momentum...
NYSE:FIX
NYSE:FIXConstruction

Will S&P 500 Entry and New Leaders in 2026 Change Comfort Systems USA's (FIX) Narrative?

Comfort Systems USA recently announced that Chief Operating Officer Trent T. McKenna will become President and COO in 2026, alongside a planned handover in the General Counsel role as long-serving legal head Laura F. Howell retires and is succeeded by Rachel R. Eslicker. These leadership changes come as Comfort Systems USA prepares to join the S&P 500 index, a move that underscores its growing scale, liquidity and visibility with institutional investors. We’ll now explore how Comfort Systems...
NYSE:FCX
NYSE:FCXMetals and Mining

Does Freeport-McMoRan’s 2025 Rally Match Its Long Term Cash Flow Potential?

Wondering if Freeport-McMoRan is still a smart way to play copper and gold, or if the recent run means you missed it? You are not alone, and that is exactly what we are going to unpack here. The stock has climbed 3.7% over the last week, 23.3% in the last month, and is now up 29.8% year to date and 111.8% over five years, which indicates the market is steadily repricing its long term prospects. Those moves have come as investors focus on tightening copper supply, rising long term demand from...
NYSE:DHR
NYSE:DHRLife Sciences

Danaher (DHR): Revisiting Valuation as Earnings Grow While the Share Price Stalls

Danaher (DHR) has been treading water lately, with the stock roughly flat over the past year even as fundamentals quietly improve. That gap between steady earnings growth and muted price action is what makes the setup interesting. See our latest analysis for Danaher. At around $224.84 per share, Danaher’s 90 day share price return of 18.05 percent stands out against a softer year long total shareholder return of roughly flat. This suggests momentum is starting to rebuild as investors reassess...
NYSE:AA
NYSE:AAMetals and Mining

Alcoa (AA) Is Up 11.1% After Analyst Upgrades And Earnings Revisions - Has The Bull Case Changed?

Recently, several major research firms including Citigroup, UBS, JP Morgan, BMO and HSBC reiterated or lifted their views on Alcoa, while Zacks raised its earnings consensus and ranking after stronger estimate revisions and relative momentum, reinforcing a shift in sentiment that has already taken place. Alcoa also announced in the past that it will report its fourth-quarter and full-year 2025 results on January 22, 2026, giving investors a near-term catalyst to test whether the improving...
NYSE:AGM
NYSE:AGMDiversified Financial

Assessing Federal Agricultural Mortgage (AGM) Valuation After Recent Pullback and 3‑Year Outperformance

Federal Agricultural Mortgage (AGM) has quietly outperformed many financial peers over the past 3 years, even as the stock has slipped about 8% this year, inviting a closer look at its setup. See our latest analysis for Federal Agricultural Mortgage. At around $177 per share, the recent pullback, including a modest year to date share price decline, sits against a much stronger backdrop: a three year total shareholder return of about 70 percent, suggesting longer term momentum has not fully...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Alleged Employee Poaching And Branch Closures Might Change The Case For Investing In Old National Bancorp (ONB)

Old National Bank has filed a lawsuit against Bell Bank alleging a coordinated mass resignation of eight senior employees from its Brainerd and Baxter, Minnesota branches, along with the misuse of confidential information and customer relationships that disrupted operations and led to branch closures. The case highlights how competition for experienced bankers and local client relationships can affect Old National’s regional presence, operational continuity, and customer retention in its...
NYSE:USB
NYSE:USBBanks

Assessing U.S. Bancorp’s Valuation After Analyst Upgrades and Strong Recent Profit Growth

U.S. Bancorp (USB) is back on investors radar as Wall Street leans more optimistic, with several firms reaffirming constructive views ahead of Q4 earnings after the bank delivered an 18% profit jump in Q3. See our latest analysis for U.S. Bancorp. The upbeat Q3 and steady dividend signals seem to be feeding into the tape, with a roughly 13% year to date share price return and an 18% one year total shareholder return suggesting momentum is building rather than fading at the current share price...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Does Catalyst Pharmaceuticals Rally Still Offer Value After 594% Five Year Surge?

Wondering if Catalyst Pharmaceuticals is still a smart buy after its huge multi year run, or if most of the upside is already priced in? This breakdown will help you consider whether the current share price offers real value or is primarily driven by momentum. The stock has continued to grind higher, with gains of 0.5% over the last week, 2.0% over the last month, 10.3% year to date, 11.6% over the past year, and 594.2% over five years. Recent market interest has been shaped by the company...
NasdaqGS:AMPH
NasdaqGS:AMPHPharmaceuticals

Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025?

Wondering if Amphastar Pharmaceuticals at around $26.60 is a hidden bargain or a value trap? This breakdown will help you decide whether it still deserves a spot on your watchlist. The stock has bounced 5.3% over the last week and 2.3% over the past month, even though it is still down 26.8% year to date and 32.0% over the last year. Investors have been reacting to a mix of pipeline updates, regulatory developments, and shifting sentiment across the broader generics and specialty pharma...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Evaluating Duolingo (DUOL) After Strong Growth, Record Conversions and Improving Free Cash Flow

Recent commentary around Duolingo (DUOL) has focused on its rapid revenue growth, improving user conversion, and steady free cash flow, giving investors fresh reasons to revisit the stock after a choppy year. See our latest analysis for Duolingo. Those fundamentals are starting to show up in the tape, with the latest share price of $185.96 coming after a 7.63% one month share price return but a steep 39.88% three month share price decline, leaving the three year total shareholder return still...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile?

Septerna, Inc. recently announced that CEO and co-founder Jeffrey Finer will present the company’s G protein-coupled receptor drug discovery platform at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, with a live webcast and 30-day archive available to investors. Investor attention has also increased after Raymond James began covering Septerna with a positive view, highlighting growing institutional interest in the company’s clinical-stage...